pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS
Genzyme Europe
Apellis Europe B.V.
Genzyme Europe clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA HQ
1981 Founded
273 Employees
Public company Type
APLS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
- Founded
- 1981
- Employees
- 273
- Programs
- 20
- Drugs
- 5
- Patents
- 24
Genzyme Europe projects
1 ClinicalTrials.gov programs sponsored by Genzyme Europe.
Genzyme Europe has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Genzyme Europe have?
1 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.